90 related articles for article (PubMed ID: 23562623)
1. Characterization of a novel high-potency positive modulator of K(v)7 channels.
Dalby-Brown W; Jessen C; Hougaard C; Jensen ML; Jacobsen TA; Nielsen KS; Erichsen HK; Grunnet M; Ahring PK; Christophersen P; Strøbæk D; Jørgensen S
Eur J Pharmacol; 2013 Jun; 709(1-3):52-63. PubMed ID: 23562623
[TBL] [Abstract][Full Text] [Related]
2. Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania.
Redrobe JP; Nielsen AN
Behav Brain Res; 2009 Mar; 198(2):481-5. PubMed ID: 19162078
[TBL] [Abstract][Full Text] [Related]
3. Underlying mechanism of regulatory actions of diclofenac, a nonsteroidal anti-inflammatory agent, on neuronal potassium channels and firing: an experimental and theoretical study.
Huang CW; Hung TY; Liao YK; Hsu MC; Wu SN
J Physiol Pharmacol; 2013 Jun; 64(3):269-80. PubMed ID: 23959723
[TBL] [Abstract][Full Text] [Related]
4. Enhanced in vitro CA1 network activity in a sodium channel β1(C121W) subunit model of genetic epilepsy.
Hatch RJ; Reid CA; Petrou S
Epilepsia; 2014 Apr; 55(4):601-8. PubMed ID: 24605816
[TBL] [Abstract][Full Text] [Related]
5. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.
Korsgaard MP; Hartz BP; Brown WD; Ahring PK; Strøbaek D; Mirza NR
J Pharmacol Exp Ther; 2005 Jul; 314(1):282-92. PubMed ID: 15814569
[TBL] [Abstract][Full Text] [Related]
6. Effect of the new antiepileptic drug retigabine in a rodent model of mania.
Dencker D; Dias R; Pedersen ML; Husum H
Epilepsy Behav; 2008 Jan; 12(1):49-53. PubMed ID: 18086455
[TBL] [Abstract][Full Text] [Related]
7. Antimanic Efficacy of a Novel Kv3 Potassium Channel Modulator.
Parekh PK; Sidor MM; Gillman A; Becker-Krail D; Bettelini L; Arban R; Alvaro GS; Zambello E; Mutinelli C; Huang Y; Large CH; McClung CA
Neuropsychopharmacology; 2018 Jan; 43(2):435-444. PubMed ID: 28857068
[TBL] [Abstract][Full Text] [Related]
8. Multi-walled carbon nanotube increases the excitability of hippocampal CA1 neurons through inhibition of potassium channels in rat's brain slices.
Chen T; Yang J; Ren G; Yang Z; Zhang T
Toxicol Lett; 2013 Feb; 217(2):121-8. PubMed ID: 23274715
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of ethanol action on midbrain dopaminergic neuron firing: a dynamic-clamp study of the role of I(h) and GABAergic synaptic integration.
Tateno T; Robinson HP
J Neurophysiol; 2011 Oct; 106(4):1901-22. PubMed ID: 21697445
[TBL] [Abstract][Full Text] [Related]
10. Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370.
Jepps TA; Bentzen BH; Stott JB; Povstyan OV; Sivaloganathan K; Dalby-Brown W; Greenwood IA
Br J Pharmacol; 2014 Oct; 171(19):4413-24. PubMed ID: 24909207
[TBL] [Abstract][Full Text] [Related]
11. K(v) 7 (KCNQ) channel openers normalize central 2-deoxyglucose uptake in a mouse model of mania and increase prefrontal cortical and hippocampal serine-9 phosphorylation levels of GSK3β.
Kristensen LV; Sandager-Nielsen K; Hansen HH
J Neurochem; 2012 May; 121(3):373-82. PubMed ID: 22356228
[TBL] [Abstract][Full Text] [Related]
12. A small molecule activator of Na
Frederiksen K; Lu D; Yang J; Jensen HS; Bastlund JF; Larsen PH; Liu H; Crestey F; Dekermendjian K; Badolo L; Laursen M; Hougaard C; Yang C; Svenstrup N; Grunnet M
Eur J Neurosci; 2017 Aug; 46(3):1887-1896. PubMed ID: 28635024
[TBL] [Abstract][Full Text] [Related]
13. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.
Hansen HH; Ebbesen C; Mathiesen C; Weikop P; Rønn LC; Waroux O; Scuvée-Moreau J; Seutin V; Mikkelsen JD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1006-19. PubMed ID: 16775195
[TBL] [Abstract][Full Text] [Related]
14. Effects of barbiturates on ATP-sensitive K channels in rat substantia nigra.
Ohtsuka T; Ishiwa D; Kamiya Y; Itoh H; Nagata I; Saito Y; Yamada Y; Sumitomo M; Andoh T
Neuroscience; 2006; 137(2):573-81. PubMed ID: 16289884
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta.
Wu C; Yang K; Liu Q; Wakui M; Jin GZ; Zhen X; Wu J
Neuropharmacology; 2010 Dec; 59(7-8):567-72. PubMed ID: 20804776
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of neuronal hyperexcitability caused by partial inhibition of Na+-K+-ATPases in the rat CA1 hippocampal region.
Vaillend C; Mason SE; Cuttle MF; Alger BE
J Neurophysiol; 2002 Dec; 88(6):2963-78. PubMed ID: 12466422
[TBL] [Abstract][Full Text] [Related]
17. Retigabine: chemical synthesis to clinical application.
Blackburn-Munro G; Dalby-Brown W; Mirza NR; Mikkelsen JD; Blackburn-Munro RE
CNS Drug Rev; 2005; 11(1):1-20. PubMed ID: 15867950
[TBL] [Abstract][Full Text] [Related]
18. Expression and functional properties of TRPM2 channels in dopaminergic neurons of the substantia nigra of the rat.
Chung KK; Freestone PS; Lipski J
J Neurophysiol; 2011 Dec; 106(6):2865-75. PubMed ID: 21900507
[TBL] [Abstract][Full Text] [Related]
19. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
20. Hypothetical dopamine dynamics in mania and psychosis--its pharmacokinetic implications.
Park SY; Kang UG
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():89-95. PubMed ID: 23268190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
